DCOY earnings analysis
What we found in DCOY's 10-Q: the parts that mattered, the offsets in the same document, and what the company said about what comes next.
Our reading of the filing · Free to read, no account needed
The supplied 10-Q text does not include the current-quarter income statement, balance sheet, cash flow statement or MD&A figures, so revenue, margin, cash-flow and segment trends cannot be quantified. The prior reported diluted EPS was negative $4.18 in Q1 2026, and no current-quarter EPS is disclosed in the supplied text. Sentiment remains bearish because the filing adds a potentially immediate Nasdaq delisting risk tied to a $5.0 million market-value threshold and 30 consecutive trading days below it.
The parts that mattered.
Pulled out of the filing itself, with the figures the company reported.
- Controls remained effective
- Management concluded that disclosure controls and procedures were effective at the reasonable-assurance level as of June 30, 2026, and reported no significant change in internal control during the three months ended June 30, 2026.
- No material legal proceedings
- The company reported that it was not a party to any material legal proceedings as of August 12, 2026, although ordinary-course claims could still become material.
And the other side of it.
The offsets in the same document — the things a summary that only listed the good news would have left out.
- Potential Nasdaq delisting
- A Nasdaq rule approved on July 22, 2026 would require at least $5.0 million of market value of listed securities; below that threshold for 30 consecutive trading days could result in immediate delisting without a cure period. The company states its Common Stock is currently below the proposed $5.0 million threshold.
- Dilution and financing pressure
- If the $5.0 million Nasdaq market-value rule becomes effective, the company may need to issue securities or raise additional capital to regain compliance, potentially diluting existing shareholders and increasing costs.
- Reduced liquidity if delisted
- If delisted, the company may seek OTCQX quotation, but it states that OTCQX could involve significantly less trading volume, analyst coverage and investor interest, potentially reducing trading prices and capital-market access.
What they said about what is next.
No quantitative revenue or EPS outlook is provided in the supplied 10-Q text; numeric guidance fields are therefore null.
The filing reads worse than the one before it.
What came before.
- 10-Q · May 8, 2026
- DCOY's Q1 2026 results reveal continued challenges with a net loss of $2.22 million, a significant increase from $1.71 million in Q1 2025, highlighting ongoing financial strain. Research and development expenses surged…
- 10-K · April 30, 2026
- DCOY's 10-K reveals a strategic focus on advancing its cancer immunotherapy pipeline through innovative computational modeling. Despite previous successes, faced with significant challenges, the firm projects a…
This is our reading of a public filing, not the filing. Read the original on SEC.gov · Educational only. Nothing here is investment advice.
Read the next one first.
We read every filing DCOY makes the day it lands, and put it next to what the options market did about it. Members get both, and an alert when a filing arrives.
Cancel anytime · Month to month · Switch tiers whenever